Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00412737 · ClinicalTrials.gov registry record · Phase 4
A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised Participants
A Phase 4 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 4
- Development phase
- 477
- Enrollment target
NCT00412737 is a Phase 4 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 477 participants.
The verdict
NCT00412737, a Phase 4 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 477 participants
- Enrollment target
Study Summary
This 2 arm study will evaluate the efficacy and safety of oseltamivir in the seasonal prophylaxis of influenza in immunocompromised participants (as represented by transplant recipients). Transplant recipients enrolled when influenza is circulating in the community will be randomized to receive oseltamivir syrup or capsules 30 milligrams (mg) to 75 mg daily (depending on body weight) or placebo for 12 weeks. Influenza symptoms and safety data will be recorded throughout the study.
Interventions
- DRUG Placebo
- DRUG Oseltamivir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 477 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00412737
The ClinicalTrials.gov registry entry for NCT00412737 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 477 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00412737 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00412737 about?
NCT00412737 is a clinical study titled "A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised Participants". This 2 arm study will evaluate the efficacy and safety of oseltamivir in the seasonal prophylaxis of influenza in immunocompromised participants (as represented by transplant recipients). Transplant recipients enrolled when influenza is circulating in the community will be randomized to receive osel...
What is the current status of trial NCT00412737?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 477 participants. The study started on 2007-01. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00412737?
The interventions under investigation include: Placebo (DRUG), Oseltamivir (DRUG).
Who is sponsoring clinical trial NCT00412737?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.